Global Information
회사소개 | 문의 | 비교리스트

TAT(Trans-Activator Of Transcription) : 파이프라인 리뷰

Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 365804
페이지 정보 영문 44 Pages
가격
US $ 3,500 ₩ 4,230,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,460,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,690,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


TAT(Trans-Activator Of Transcription) : 파이프라인 리뷰 Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 44 Pages

TAT(Trans-Activator Of Transcription)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

TAT(Trans-Activator Of Transcription) 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

  • 단일요법/복합요법별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Akshaya Bio Inc.
  • Biosantech SA

치료제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 16.09.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary

Global Markets Direct's, 'Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016', provides in depth analysis on Trans Activator Of Transcription (Tat) targeted pipeline therapeutics.

The report provides comprehensive information on the Trans Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Trans Activator Of Transcription (Tat)
  • The report reviews Trans Activator Of Transcription (Tat) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Trans Activator Of Transcription (Tat) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Trans Activator Of Transcription (Tat) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Trans Activator Of Transcription (Tat)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Trans Activator Of Transcription (Tat) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Trans Activator Of Transcription (Tat) Overview
  • Therapeutics Development
    • Trans Activator Of Transcription (Tat) - Products under Development by Stage of Development
    • Trans Activator Of Transcription (Tat) - Products under Development by Therapy Area
    • Trans Activator Of Transcription (Tat) - Products under Development by Indication
  • Trans Activator Of Transcription (Tat) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Trans Activator Of Transcription (Tat) - Products under Development by Companies
  • Trans Activator Of Transcription (Tat) - Products under Development by Universities/Institutes
  • Trans Activator Of Transcription (Tat) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Trans Activator Of Transcription (Tat) - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc
    • Biosantech SA
    • Cannabis Science Inc
  • Trans Activator Of Transcription (Tat) - Drug Profiles
    • CSTATI-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV-1 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Tat and Rev for HIV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Trans Activator Of Transcription (Tat) - Dormant Projects
  • Trans Activator Of Transcription (Tat) - Discontinued Products
  • Trans Activator Of Transcription (Tat) - Featured News & Press Releases
    • Jun 08, 2016: Improving the Effect of HIV Drugs by Use of the Tat Vaccine
    • Mar 15, 2016: Publication in Retrovirology of the results of Biosantech's phase IIA clinical trial for the anti-HIV candidate vaccine
    • Jul 29, 2015: Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV and Kaposi Sarcoma Drug Development Program
    • Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests
    • Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
    • Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
    • Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma
    • Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Akshaya Bio Inc, H2 2016
  • Pipeline by Biosantech SA, H2 2016
  • Pipeline by Cannabis Science Inc, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q